Stock Market Reviews

RVTY (Revvity, Inc.) News

Get the latest news, insights, and market updates on RVTY (Revvity, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• 3 Unpopular Stocks with Open Questions
  Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
  Dec 4, 2025 - $RVTY
• VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique d'Investissement, as part of the France 2030 plan, during the official ceremony held yesterday, December
  Dec 4, 2025 - $RVTY
• Revvity (RVTY): Evaluating Valuation Following Latest Financial Results and Share Price Rebound
  Revvity (RVTY) shares have drawn investor attention after the company released its latest financial results, which highlight annual growth in both revenue and net income. The market is reacting to these numbers, particularly in the context of recent sector trends. See our latest analysis for Revvity. Revvity's stock rebounded strongly this past week, with a seven-day share price return of over 13 percent. This helped to reverse some of the pressure seen earlier this year. Still, with a...
  Nov 27, 2025 - $RVTY
• Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?
  Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Nov 26, 2025 - $RVTY
• Option Care Health, DaVita, Revvity, West Pharmaceutical Services, and Bausch + Lomb Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025 - $RVTY
• Revvity Stock Outlook: Is Wall Street Bullish or Bearish?
  Revvity has notably underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
  Nov 19, 2025 - $RVTY
• 1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Ignore
  Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
  Nov 13, 2025 - $RVTY
• Some Investors May Be Willing To Look Past Revvity's (NYSE:RVTY) Soft Earnings
  Investors were disappointed with the weak earnings posted by Revvity, Inc. ( NYSE:RVTY ). Despite the soft profit...
  Nov 12, 2025 - $RVTY
• 3 Cash-Producing Stocks That Fall Short
  Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
  Nov 10, 2025 - $RVTY
• Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
  WALTHAM, Mass., November 10, 2025--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acc
  Nov 10, 2025 - $RVTY